Literature DB >> 16263796

Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins.

Ellen R A Van Gulck1, Peter Ponsaerts, Leo Heyndrickx, Katleen Vereecken, Filip Moerman, Ann De Roo, Robert Colebunders, Glenn Van den Bosch, Dirk R Van Bockstaele, Viggo F I Van Tendeloo, Sabine Allard, Bernard Verrier, Concepción Marañón, Guillaume Hoeffel, Anne Hosmalin, Zwi N Berneman, Guido Vanham.   

Abstract

Infection with human immunodeficiency virus type 1 (HIV-1) is characterized by dysfunction of HIV-1-specific T cells. To control the virus, antigen-loaded dendritic cells (DCs) might be useful to boost and broaden HIV-specific T-cell responses. In the present study, monocyte-derived DCs from nontreated HIV-1-seropositive patients were electroporated with codon-optimized ("humanized") mRNA encoding consensus HxB-2 (hHXB-2) Gag protein. These DCs elicited a strong HIV-1 Gag-specific interferon-gamma (IFN-gamma) response by an HLA-A2-restricted CD8+ T-cell line. Moreover, hHXB-2 gag mRNA-electroporated DCs also triggered IFN-gamma secretion by autologous peripheral blood mononuclear cells (PBMCs), CD4+ T cells, and CD8+ T cells from all patients tested. Next, a novel strategy was developed using autologous virus sequences. Significant specific IFN-gamma T-cell responses were induced in all patients tested by DCs electroporated with patients' autologous polymerase chain reaction (PCR)-amplified and in vitro-transcribed proviral and plasma viral mRNA encoding either Gag or Env. The stimulatory effect was seen on PBMCs, CD8+ T cells, and CD4+ T cells, demonstrating both major histocompatibility complex (MHC) class I and MHC class II antigen presentation. Moreover, a significant interleukin-2 (IL-2) T-cell response was induced by DCs electroporated with hHxB-2 or proviral gag mRNA. These findings open a major perspective for the development of patient-specific immunotherapy for HIV-1 disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16263796     DOI: 10.1182/blood-2005-01-0339

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs.

Authors:  Brenda De Keersmaecker; Sabine D Allard; Patrick Lacor; Rik Schots; Kris Thielemans; Joeri L Aerts
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

Review 2.  Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis.

Authors:  Diana Finzi; Susan F Plaeger; Carl W Dieffenbach
Journal:  Clin Vaccine Immunol       Date:  2006-07

3.  Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice.

Authors:  Kilian Weigand; Franziska Voigt; Jens Encke; Birgit Hoyler; Wolfgang Stremmel; Christoph Eisenbach
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

Review 4.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 5.  Microscale electroporation: challenges and perspectives for clinical applications.

Authors:  Won Gu Lee; Utkan Demirci; Ali Khademhosseini
Journal:  Integr Biol (Camb)       Date:  2009-01-29       Impact factor: 2.192

6.  Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines.

Authors:  Charlotte Pollard; Joanna Rejman; Winni De Haes; Bernard Verrier; Ellen Van Gulck; Thomas Naessens; Stefaan De Smedt; Pieter Bogaert; Johan Grooten; Guido Vanham; Stefaan De Koker
Journal:  Mol Ther       Date:  2012-09-25       Impact factor: 11.454

7.  High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-type viral mRNA but not DNA.

Authors:  Nada M Melhem; Sherrianne M Gleason; Xiang Dong Liu; Simon M Barratt-Boyes
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

8.  Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.

Authors:  Jean-Pierre Routy; Mohamed-Rachid Boulassel; Bader Yassine-Diab; Charles Nicolette; Don Healey; Renu Jain; Claire Landry; Oleg Yegorov; Irina Tcherepanova; Tamara Monesmith; Lothar Finke; Rafick-Pierre Sékaly
Journal:  Clin Immunol       Date:  2009-11-04       Impact factor: 3.969

Review 9.  Dendritic cell-based human immunodeficiency virus vaccine.

Authors:  C R Rinaldo
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

10.  Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals.

Authors:  Ellen R Van Gulck; Guido Vanham; Leo Heyndrickx; Sandra Coppens; Katleen Vereecken; Derek Atkinson; Eric Florence; Ilse Kint; Zwi Nisan Berneman; Viggo Van Tendeloo
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.